@article {ALIBERTI1859, author = {CAMILLO ALIBERTI and RICCARDO CARANDINA and DONATELLA SARTI and ENRICO PIZZIRANI and GAETANO RAMONDO and LUCA MULAZZANI and GIAN MARIA MATTIOLI and GIAMMARIA FIORENTINI}, title = {Chemoembolization with Drug-eluting Microspheres Loaded with Doxorubicin for the Treatment of Cholangiocarcinoma}, volume = {37}, number = {4}, pages = {1859--1863}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: To report clinical outcomes of transarterial chemoembolization (TACE) using drug-eluting beads (DEBs) loaded with doxorubicin for the treatment of unresectable intrahepatic cholangiocarcinoma (CCA). Patients and Methods: We treated 127 patients with doxorubicin via TACE. Inclusion criteria were: diagnosis of unresectable CCA; indication for TACE, performance status (PS) 0-2, \>3 months of life expectancy, \>18 years old, written consent. TACE was performed using DEBs for 109 (86\%) patients and polythylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin for 18 (14\%) patients. Results: Tumor response of the whole sample of 127 patients was partial response (PR) in 19 (15\%) patients, stable disease (SD) in 101 (80\%) and progressive disease (PD) in seven (5\%) 3 months after therapy, with no complete responses. There were differences between type of embolics: PR was 7\% and 77\%, SD was 88\% and 8\%, and PD was 5\% and 15\%, and the disease control rate was 95\% and 85\% in the DEB and PEG groups, respectively. Most frequent side-effects were: abdominal pain, fever, nausea, and transaminase rise. Conclusion: TACE was effective and safe for CCA treatment, with a high disease control rate. The best response of PEG-TACE was PR, whereas it was SD for DEB-TACE.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/4/1859}, eprint = {https://ar.iiarjournals.org/content/37/4/1859.full.pdf}, journal = {Anticancer Research} }